Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study

BACKGROUND: Camptothecin (CPT) and its derivatives are currently used as second- or third-line treatment for patients with endocrine-resistant breast cancer (BC). These drugs convert nuclear enzyme DNA topoisomerase I (TOP1) to a cell poison with the potential to damage DNA by increasing the half-li...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Tesauro, Cinzia, Simonsen, Anne Katrine, Andersen, Marie Bech, Petersen, Kamilla Wandsoe, Kristoffersen, Emil Laust, Algreen, Line, Hansen, Noriko Yokoyama, Andersen, Anne Bech, Jakobsen, Ann Katrine, Stougaard, Magnus, Gromov, Pavel, Knudsen, Birgitta R., Gromova, Irina
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6884793/
https://ncbi.nlm.nih.gov/pubmed/31783818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6371-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi